HUP0100928A2 - Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk - Google Patents

Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk

Info

Publication number
HUP0100928A2
HUP0100928A2 HU0100928A HUP0100928A HUP0100928A2 HU P0100928 A2 HUP0100928 A2 HU P0100928A2 HU 0100928 A HU0100928 A HU 0100928A HU P0100928 A HUP0100928 A HU P0100928A HU P0100928 A2 HUP0100928 A2 HU P0100928A2
Authority
HU
Hungary
Prior art keywords
peptide analogues
insulin
diabetes
treatment
amino acids
Prior art date
Application number
HU0100928A
Other languages
English (en)
Inventor
Paul J. Conlon
Amitabh Gaur
Nicholas Ling
Original Assignee
Neurocrine Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences, Inc. filed Critical Neurocrine Biosciences, Inc.
Publication of HUP0100928A2 publication Critical patent/HUP0100928A2/hu
Publication of HUP0100928A3 publication Critical patent/HUP0100928A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány szerinti, humán inzulin B-láncának 9-től 23-ig terjedőminosavait tartalmazó peptidanalógok szekvenciájukban természeteshumán inzulin B láncának 9-től 23-ig terjedő aminosavaitól 1-4aminosav helyettesítése által különböznek, ahol a 12., 13., 15. és 16.aminosavak közül legalább egy helyettesített. A találmány tárgyköréheztartoznak továbbá a fenti peptidanalógokat tartalmazó gyógyászatikészítmények és a peptidanalógok alkalmazása. Ó
HU0100928A 1998-02-23 1999-02-23 Methods for treatment of diabetes using peptide analogues of insulin HUP0100928A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2815698A 1998-02-23 1998-02-23
PCT/US1999/003915 WO1999042482A1 (en) 1998-02-23 1999-02-23 Methods for treatment of diabetes using peptide analogues of insulin

Publications (2)

Publication Number Publication Date
HUP0100928A2 true HUP0100928A2 (hu) 2001-08-28
HUP0100928A3 HUP0100928A3 (en) 2001-11-28

Family

ID=21841884

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100928A HUP0100928A3 (en) 1998-02-23 1999-02-23 Methods for treatment of diabetes using peptide analogues of insulin

Country Status (20)

Country Link
US (1) US6197926B1 (hu)
EP (1) EP1056776A1 (hu)
JP (1) JP2002504491A (hu)
KR (1) KR20010041238A (hu)
CN (1) CN1241942C (hu)
AP (1) AP2000001888A0 (hu)
AU (1) AU741037B2 (hu)
BR (1) BR9908178A (hu)
CA (1) CA2321929A1 (hu)
EA (1) EA003944B1 (hu)
HU (1) HUP0100928A3 (hu)
ID (1) ID26788A (hu)
IL (1) IL137904A0 (hu)
NO (1) NO20004198L (hu)
NZ (1) NZ506447A (hu)
OA (1) OA11453A (hu)
PL (1) PL342517A1 (hu)
SK (1) SK12412000A3 (hu)
TR (1) TR200003048T2 (hu)
WO (1) WO1999042482A1 (hu)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562942B1 (en) * 1999-02-23 2003-05-13 Neurocrine Biosciences, Inc. Methods for treatment of diabetes using peptide analogues of insulin
CN1125081C (zh) * 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
US7462486B2 (en) * 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
WO2001085154A2 (en) * 2000-05-12 2001-11-15 Oregon Health Sciences University Method of treating immune pathologies with low dose estrogen
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
US20070172453A1 (en) * 2002-08-30 2007-07-26 Vincent Geenen Tolerogenic approach for type 1 diabetes
US20040138116A1 (en) * 2002-08-30 2004-07-15 Vincent Geenen Tolerogenic approach for type 1 diabetes
US8987263B2 (en) 2002-10-10 2015-03-24 Meir Shinitzky Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
CA2527830A1 (en) * 2003-06-02 2004-12-23 Mercia Pharma, Inc. Therapeutic vaccine compositions for the treatment of type 1 diabetes
WO2006012641A2 (en) * 2004-07-30 2006-02-02 Oregon Health And Science University Methods for detecting and treating autoimmune disorders
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
DE102008003566A1 (de) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
RU2524423C2 (ru) 2008-01-09 2014-07-27 Санофи-Авентис Дойчланд Гмбх Новые производные инсулина с чрезвычайно замедленным профилем время/действие
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp PEPTIDE PRODRUGS BASED ON ESTERS
CA2740685C (en) 2008-10-17 2018-09-11 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
CN102245624B (zh) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
EP2376520B1 (en) * 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Insulin analogs
JP5973918B2 (ja) 2009-11-13 2016-08-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト及びメチオニンを含む薬学的組成物
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
US20110311536A1 (en) * 2010-06-11 2011-12-22 Dana-Farber Cancer Institute, Inc. Prevention of type 1 diabetes by treg vaccination with an insulin mimetope
JP5969469B2 (ja) 2010-06-16 2016-08-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト
JP5912112B2 (ja) 2010-06-24 2016-04-27 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ アミド系インスリンプロドラッグ
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013096386A1 (en) 2011-12-20 2013-06-27 Indiana University Research And Technology Corporation Ctp-based insulin analogs for treatment of diabetes
CN108383902A (zh) 2012-09-26 2018-08-10 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
RU2678134C2 (ru) 2013-03-14 2019-01-23 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты инсулин-инкретин
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
EP3197912B1 (en) 2014-09-24 2023-01-04 Indiana University Research & Technology Corporation Lipidated amide-based insulin prodrugs
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN111925420B (zh) * 2019-12-11 2022-04-01 山东大学 一种多肽作为嗅觉受体Olfr109激动剂配体的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5559094A (en) * 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
US5594100A (en) * 1995-02-22 1997-01-14 Regents Of The University Of Colorado Epitope for prevention of type I diabetes
JPH11509195A (ja) * 1995-06-30 1999-08-17 ノボ ノルディスク アクティーゼルスカブ 糖尿病の特徴を有する疾患の予防

Also Published As

Publication number Publication date
HUP0100928A3 (en) 2001-11-28
KR20010041238A (ko) 2001-05-15
NO20004198L (no) 2000-10-20
NO20004198D0 (no) 2000-08-22
US6197926B1 (en) 2001-03-06
SK12412000A3 (sk) 2002-05-09
PL342517A1 (en) 2001-06-18
AU741037B2 (en) 2001-11-22
BR9908178A (pt) 2002-01-15
CN1294597A (zh) 2001-05-09
AU2783199A (en) 1999-09-06
JP2002504491A (ja) 2002-02-12
OA11453A (en) 2003-12-08
TR200003048T2 (tr) 2000-12-21
ID26788A (id) 2001-02-08
CN1241942C (zh) 2006-02-15
NZ506447A (en) 2002-11-26
CA2321929A1 (en) 1999-08-26
EP1056776A1 (en) 2000-12-06
EA003944B1 (ru) 2003-10-30
IL137904A0 (en) 2001-10-31
WO1999042482A1 (en) 1999-08-26
AP2000001888A0 (en) 2000-09-30
EA200000872A1 (ru) 2001-02-26

Similar Documents

Publication Publication Date Title
HUP0100928A2 (hu) Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
HUP0004560A2 (hu) Törést gyógyító PTHrP analógok
HUP0003349A2 (hu) Mellékpajzsmirigy-hormon peptidanalógok, ezeket hatóanyagként tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0003314A2 (hu) GLP-1 analógok és származékok alkalmazása elhízás szabályozására használható gyógyszerkészítmények előállítására
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
ATE266043T1 (de) Peptidanaloge des menschlichen basischen myelinproteins
EA200000748A1 (ru) Способ введения мономерных аналогов инсулина
MXPA02006679A (es) Composicion farmaceutica.
ATE75945T1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
ATE273997T1 (de) Zyklische hexapeptid somatostatin analoga
HUP0000432A2 (hu) Inzulin C-peptidek
MX9703642A (es) Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.
ATE377026T1 (de) Behandlung von fettleibigkeit
CY1110487T1 (el) Χρηση της lh σε ελεγχομενη υπερδιεγερση των ωοθηκων
SE9702401D0 (sv) Pharmaceutical use
MX9704738A (es) Analogos de peptido p277 y composiciones farmaceuticas que los contienen, metodo de diagnostico de diabetes mellitus dependiente de la insulina y uso de los mismos.
ATE211391T1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
ATE103294T1 (de) Peptidfragmente von hiv.
HUP0202793A2 (hu) A humán inzulin monomer analógjai
ATE283279T1 (de) Therapeutische inhaltsstoffe
RU95120588A (ru) Циклогексапептиды, их смеси, способ их получения и применения
YU64192A (sh) Analozi insulina
ES2071038T3 (es) Peptidos asociados al hiv.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees